Characterization of solid state forms of glipizide

Powder Technology

Volumn 264, Issue , 2014, Pages 365-376

  Renuka, ^a   Singh, Sachin Kumar ^a   Gulati, Monica ^a   Kaur, Inderpreet ^b  

^a LOVELY PROFESSIONAL UNIVERSITY   (India)

^b CSIR CENTRAL SCIENTIFIC INSTRUMENTS ORGANISATION   (India)

Author keywords

Capsule dosage form; Crystal forms; Form III; Form V; Glipizide

Indexed keywords

CRYSTALLINE MATERIALS; DYE-SENSITIZED SOLAR CELLS; RAMAN SPECTROSCOPY; VAPORS;

CRYSTAL FORMS; DOSAGE FORMS; FORM III; GLIPIZIDE;

DISSOLUTION;

CHLOROFORM; GLIPIZIDE; METHANOL;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DISSOLUTION; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG STABILITY; PARTICLE SIZE; PH; POWDER; PRECIPITATION; RAMAN SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMOGRAPHY; X RAY POWDER DIFFRACTION;

EID: 84904612277     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2014.05.062     Document Type: Article

References (26)

1. Saha B.K., Nangia A., Jasko S.M. Crystal engineering with hydrogen bonds and halogen bonds. Cryst. Eng. Commun. 2005, 7:355-358.
2. Chadha R., Gupta S., Shukla G. Crystal habit, characterization and pharmacological activity of various crystal forms of arteether. Acta Pharm. Sin. B 2011, 1:129-135.
3. Brittain H.G. Polymorphism and solvatomorphism. J. Pharm. Sci. 2007, 96:705-728.
4. Romero S., Escalera B., Bustamante P. Solubility behavior of polymorphs I and II of mefenamic acid in solvent mixtures. Int. J. Pharm. 1999, 178:193-202.
5. Al-Zoubi N., Kachrimanis K., Malamatris S. Effects of harvesting and cooling on crystallization and transformation of orthorhombic paracetamol in ethanolic solution. Eur. J. Pharm. Sci. 2002, 17:13-21.
6. Garekani H., Ford J.L., Rubinstein M.H., Rajabi-Siahboomi A.R. Highly compressible paracetamol: I. Crystallization and characterization. Int. J. Pharm. 2000, 208:87-99.
7. Rasenack N., Muller B.W. Crystal habit and tableting behavior. Int. J. Pharm. 2002, 244:45-57.
8. Braga D., Grepioni F., Maini L., Polito M. Crystal polymorphism and multiple crystal forms. Mol. Netw. 2009, 25:25-50.
9. Bond A.D. Polymorphism in molecular crystals. Curr. Opin. Solid State Mater. Sci. 2009, 13:91-97.
10. Cabri W., Ghetti P., Pozzi G., Alpegiani M. Polymorphisms and patent, market, and legal battles: cefdinir case study. Org. Process. Res. Dev. 2007, 11:64-72.
11. Raw A.S., Yu L.X. Pharmaceutical solid polymorphism in drug development and regulation. Adv. Drug Deliv. Rev. 2004, 56:235-236.
12. Bartolomei M., Rodomonte A., Antoniella E., Minelli G., Bertocchi P. Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: solid-state characterisation of a trihydrate form. J. Pharm. Biomed. Anal. 2007, 45:443-449.
13. Haleblian J., McCrone W. Pharmaceutical applications of polymorphism. J. Pharm. Sci. 1969, 58:911-929.
14. Burger A., Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Microchim. Acta (Wien) 1979, 72:259-271. (II).
15. Singh S.K., Srinivasan K.K., Gowthamarajan K., Singare D.S., Prakash D., Gaikwad N.B. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur. J. Pharm. Biopharm. 2011, 78:441-446.
16. Choudhary D., Kumar S., Gupta G.D. Enhancement of solubility and dissolution of glipizide by solid dispersion (kneading) technique. Asian J. Pharm. 2009, 3:245-251.
17. Rahman A.A.A., Khidr S.H., Samy E.M., Sayed M.A. Enhancement of the dissolution rate of glipizide capsules using fenugreek as natural additive. Unique J. Pharm. Biol. Sci. 2014, 02:1-8.
18. Karanth H., Shenoy V.S., Murthy R.R. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. AAPS PharmSciTech 2006, 7:E31-E38.
19. Wang X., Michel A., Van den Mooter G. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int. J. Pharm. 2005, 303:54-61.
20. Van den Mooter G., Weuts L., Ridder T.D., Blaton N. Evaluation of inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int. J. Pharm. 2006, 316:1-6.
21. Seth N.S. Formulation and evaluation of solid dispersion of olanzepine. Int. J. Pharm. Sci. Res. 2011, 2:691-697.
22. Singh S.K., Srinivasan K.K., Singare D.S., Gowthamarajan K., Prakash D. Formulation of ternary complexes of glyburide with hydroxypropyl-β-cyclodextrin and other solubilizing agents and their effect on release behavior of glyburide in aqueous and buffered media at different agitation speeds. Drug Dev. Ind. Pharm. 2012, 38:1328-1336.
23. Barbas R., Polito M., Prohens R., Puigjaner C. Polymorphism of (S)-triphenylglycol: kinetic dependent transformation of a new multipolymorphic system. Chem. Commun. 2007, 3538-3540.
24. Brittain H.G., Grant D.J.W. Effect of polymorphism and solid-state solvation on solubility and dissolution rate. Polymorphism in Pharmaceutical Solids 1999, 279-330. Marcel Dekker, Inc., New York. H.G. Brittain (Ed.).
25. Löbmann K., Strachan C., Grohganz H., Rades T., Laitinen R., Korhonen O. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur. J. Pharm. Biopharm. 2012, 81:159-169.
26. Laitinen R., Löbmann K., Strachan C.J., Grohganz H., Rades T. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 2013, 453:65-79.